By Emily McCloskey, Manager, Policy and Legislative Affairs
Today, the National Alliance of State and Territorial AIDS Directors (NASTAD) released A Path to Policy: A Blueprint for Community Engagement and Advocacy. The toolkit is designed to assist state health departments and HIV and viral hepatitis programs build their advocacy, policy development and implementation and community engagement efforts. Continue reading
By Tibebe Shenie, Country Director, NASTAD Ethiopia and Anne Sites, Senior Manager, Global Program, NASTAD
Wubshet Denboba, Health System Strengthening Senior Specialist, NASTAD Ethiopia
The recently released UNAIDS Gap Report highlighted many significant achievements in the global fight against HIV/AIDS, including a 13% decrease in new HIV infections and a 19% reduction in AIDS-related deaths over the past three years. But the report also emphasized that much work remains to be done to ‘close the gap’ between those who have access to life-saving services and those who do not. It is critical that Ministries of Health be able to utilize high quality HIV data to address these gaps, and to direct client-level interventions to locations and populations with the greatest need. In Ethiopia, NASTAD is contributing to this effort as it supports the Federal HIV/AIDS Prevention and Control Office (FHAPCO) in the implementation of a Multi-Sectoral Response Information System (MRIS).
For immediate release: June 10, 2014
Contact: Britten Pund, 202-434-8044, bpund@NASTAD.org
Washington, DC – Today, the National Alliance of State & Territorial AIDS Directors (NASTAD) released the 2014 Online AIDS Drug Assistance Program (ADAP) Formulary Database (the Database) and accompanying User’s Guide. The Database details ADAP coverage of medications both individually and by drug class, marking the first time state-by-state ADAP formulary coverage data has been made publicly available in an online searchable format. NASTAD receives frequent requests regarding individual states’ formulary composition. This newly-released online format provides a method to query this data. Medications included in the Database include antiretroviral (ARV) treatments and “A1” Opportunistic Infections (A1 OI) medications, as well as treatments for hepatitis B and C, substance use treatment medications and various vaccines and laboratory tests. The Database includes formulary information from all 50 states as well as the District of Columbia, Guam and Puerto Rico, as of March 31, 2014. Moving forward, the Database will be updated as new information becomes available. In addition, interested parties are encouraged to contact individual ADAPs with specific questions about medication availability. Continue reading
The content of this post originally appeared in The Roll Out, a Newsletter of CDC-Ethiopia and Partners, in December 2013.
Mainstreaming HIV/AIDS in Higher Education Institutions
The Roll Out, a Newsletter of CDC-Ethiopia and Partners
Since the issue of HIV/AIDS was brought forward as one of the major health challenges of Ethiopia, lots of public and private organizations, including higher education institutions (HEI) in the country have been responding to it in many different ways. The interventions in most of these HEIs are characterized by sidelined, on the fringe activities with lack of coordination and sustainability. As HIV/AIDS continues to be a threat and constitutes a big problem among colleges and universities in Ethiopia, there is a need for comprehensive, prompt and sustainable programming. Mainstreaming brings HIV/AIDS to the center of these organizations’ agendas along with the core activities, integrating it into the main objectives of the institutions.
By Dawn Fukuda, Director, Office of HIV/AIDS, Massachusetts Department of Public Health and NASTAD Chair (Outgoing)
Director, Office of HIV/AIDS, Massachusetts Department of Public Health and NASTAD Chair
As I began my tenure as chair of the National Alliance of State and Territorial AIDS Directors (NASTAD) in May 2013, I was full of energy and optimism. January 1st of 2014 was close at hand, and represented a massive new opportunity to invigorate our response to the HIV and viral hepatitis epidemics through the implementation of the Affordable Care Act (ACA).
I was confident based on our experience with state health care reform in my home state of Massachusetts that increased access to medical care through broader insurance coverage would translate into health promotion and disease prevention outcomes that would advance our progress along the HIV Care Continuum. I remain steadfast in my belief that integrating an HIV and viral hepatitis response into primary medical care and reimbursable health services is the way to sustain our efforts into the future; yet the mechanics of the ACA roll out over the past year also provide a striking reminder of the essential and non-transferrable role of public health.